Quick Answer
SANGAMO THERAPEUTICS, INC reported R&D Expense of $112.67 million for fiscal year 2025.
SANGAMO THERAPEUTICS, INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $112.67M | +1.0% |
| 2024 | $111.52M | -52.4% |
| 2023 | $234.06M | -6.3% |
| 2022 | $249.90M | +8.3% |
| 2021 | $230.82M | +27.8% |
| 2020 | $180.65M | +23.8% |
| 2019 | $145.92M | +27.0% |
| 2018 | $114.87M | +74.8% |
| 2017 | $65.73M | +0.2% |
| 2016 | $65.62M | -2.4% |
| 2015 | $67.20M | +17.9% |
| 2014 | $56.97M | +53.8% |
| 2013 | $37.04M | +16.8% |
| 2012 | $31.71M | -1.2% |
| 2011 | $32.10M | -3.2% |
| 2010 | $33.15M | +14.4% |
| 2009 | $28.98M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $28.14M | +1.5% | +3.9% |
| June 30, 2025 | $27.08M | +11.8% | +4.1% |
| March 31, 2025 | $26.01M | -27.5% | -6.2% |
| September 30, 2024 | $27.73M | -51.4% | +14.5% |
| June 30, 2024 | $24.22M | -61.6% | -32.5% |
| March 31, 2024 | $35.89M | -43.2% | -37.1% |
| September 30, 2023 | $57.09M | -12.3% | -9.4% |
| June 30, 2023 | $63.05M | +5.0% | -0.3% |
- SANGAMO THERAPEUTICS, INC showed an increase of +1.0% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, SANGAMO THERAPEUTICS, INC’s r&d expense has grown by 288.7% (from $28.98 million to $112.67 million).
- The most recent figure is from SANGAMO THERAPEUTICS, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: